A Study of CIN-107 in Adults With Primary Aldosteronism
Public ClinicalTrials.gov record NCT04605549. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Effectiveness of CIN-107 for the Management of Blood Pressure in Patients With Primary Aldosteronism
Study identification
- NCT ID
- NCT04605549
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- AstraZeneca
- Industry
- Enrollment
- 15 participants
Conditions and interventions
Conditions
Interventions
- CIN-107 2 mg dosing Drug
- CIN-107 4 mg dosing Drug
- CIN-107 8 mg dosing Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 130 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 7, 2021
- Primary completion
- Oct 27, 2024
- Completion
- Oct 27, 2024
- Last update posted
- Mar 2, 2026
2021 – 2024
United States locations
- U.S. sites
- 10
- U.S. states
- 7
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Greenbrae | California | 94904 | — |
| Research Site | San Francisco | California | 94110 | — |
| Research Site | West Hollywood | California | 90048 | — |
| Research Site | Chicago | Illinois | 60611 | — |
| Research Site | Baltimore | Maryland | 21287 | — |
| Research Site | Ann Arbor | Michigan | 48109 | — |
| Research Site | Rochester | Minnesota | 55905 | — |
| Research Site | Cincinnati | Ohio | 45245 | — |
| Research Site | Columbus | Ohio | 43210 | — |
| Research Site | Dallas | Texas | 75390-9047 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04605549, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 2, 2026 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04605549 live on ClinicalTrials.gov.